Patents Issued in July 31, 2014
-
Publication number: 20140213526Abstract: A synthetic peptide sequence demonstrating neuroprotective and anti-inflammatory functions is disclosed. Methods of use for the synthetic peptide are also provided.Type: ApplicationFiled: March 27, 2014Publication date: July 31, 2014Applicant: Drexel UniversityInventors: Timothy J. Cunningham, Lihua Yao
-
Publication number: 20140213527Abstract: Novel peptides referred to as small humanin-like peptides (SHLPs) are provided herein along with nucleic acids encoding SHLPs and probes that selectively bind SHLPs. SHLPs have wide-ranging activity, including neuroprotective activity, anticancer activity, and cell survival activity. Also provided herein are therapeutic methods comprising administering an effective amount of an SHLP to a subject in need of treatment.Type: ApplicationFiled: December 19, 2013Publication date: July 31, 2014Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Pinchas COHEN, Laura J. Cobb
-
Publication number: 20140213528Abstract: The invention relates to IHG-1 (induced by high glucose-1) a novel gene which encodes a protein that amplifies fibrotic responses in in vitro and in vivo models of fibrotic disorders and in human diabetic nephropathy. In particular the invention relates to modifications of the IHG-1 structure which are potential fibrosuppressant biotherapeutics and modify cellular invasiveness. The invention also relates to a method of screening a therapeutic agent for suitability for the treatment of fibrotic disease comprising testing a candidate therapeutic agent for the ability to reduce the expression of IHG-1 levels in a model system.Type: ApplicationFiled: January 30, 2014Publication date: July 31, 2014Applicant: University College Dublin, National University of IrelandInventors: Catherine Godson, Madeline Murphy, Finian Martin, Victoria McEaneney
-
Publication number: 20140213529Abstract: The invention provides a Pseudomonas exotoxin A (PE) comprising an amino acid sequence having a substitution of one or more of amino acid residues E420, D463, Y481, L516, R563, D581, D589, and K606, wherein the amino acid residues are defined by reference to SEQ ID NO: 1. The invention further provides related chimeric molecules, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions. Methods of treating or preventing cancer in a mammal, methods of inhibiting the growth of a target cell, methods of producing the PE, and methods of producing the chimeric molecule are further provided by the invention.Type: ApplicationFiled: September 13, 2012Publication date: July 31, 2014Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Ira H. Pastan, Masanori Onda, Wenhai Liu
-
Publication number: 20140213530Abstract: This disclosure demonstrates that inhibition of Sirt5 can suppress malignant transformation of cells. Therefore, methods of treating cancer based on inhibition of Sirt5 are disclosed.Type: ApplicationFiled: September 7, 2012Publication date: July 31, 2014Applicant: CORNELL UNIVERSITYInventors: Hening Lin, Richard Cerione
-
Publication number: 20140213531Abstract: Template-fixed ?-hairpin peptidomimetics of the general formulae wherein Z is a chain of 11 ?-amino acid residues which, depending on their positions in the chain (counted starting from the N-terminal amino acid) are Gly, or Pro, or Pro(4NHCOPhe), or of certain types which, as the remaining symbols in the above formula, are defined in the description and the claims, and salts thereof, have the property to inhibit proteases, in particular serine proteases, especially Cathepsin G or Elastase or Tryptase. These ?-hairpin peptidomimetics can be manufactured by processes which are based on a mixed solid- and solution phase synthetic strategy.Type: ApplicationFiled: December 9, 2013Publication date: July 31, 2014Applicants: Universitat Zurich, Polyphor Ltd.Inventors: Steven J. Demarco, Kerstin Moehle, Heiko Henze, Odile Sellier, Francoise Jung, Frank Gombert, Daniel Obrecht, Christian Ludin
-
Publication number: 20140213532Abstract: This invention provides compositions and methods for enhancing delivery of drugs and other agents across epithelial tissues, including the skin, gastrointestinal tract, pulmonary epithelium, ocular tissues and the like. The compositions and methods are also useful for delivery across endothelial tissues, including the blood brain barrier. The compositions and methods employ a delivery enhancing transporter that has sufficient guanidine or amidino sidechain moieties to enhance delivery of a compound conjugated to the reagent across one or more layers of the tissue, compared to the non-conjugated compound. The delivery-enhancing polymers include, for example, poly-arginine molecules that are preferably between about 6 and 25 residues in length.Type: ApplicationFiled: December 24, 2013Publication date: July 31, 2014Applicant: KAI PHARMACEUTICALS, INC.Inventors: Jonathan B. Rothbard, Paul A. Wender, Leo P. McGrane, Lalitha V.S. Sista, Thorsten A. Kirschberg
-
Publication number: 20140213533Abstract: Methods for prevention and treatment of kidney transplant rejection are described that involve determination, analysis and computation of a 3-gene molecular signature of levels of specific RNAs (IP-10 mRNA, CD3? mRNA, and 18S rRNA) in urinary sample cells. The methods and devices described herein are diagnostic and prognostic of acute cellular rejection in kidney allografts.Type: ApplicationFiled: January 31, 2014Publication date: July 31, 2014Inventors: Manikkam Suthanthiran, Ruchuang Ding, Joseph E. Schwartz, Abraham Shaked
-
Publication number: 20140213534Abstract: Compositions for and methods of preventing or reducing the severity intestinal hyperpermeabilization in an individual are disclosed. Compositions for and methods of preventing or reducing the severity of a disease or condition caused or exacerbated by intestinal hyperpermeabilization in an individual identified as being at risk of a disease or condition caused or exacerbated by intestinal hyperpermeabilization are also disclosed. Compositions for and methods of treating an individual who has been identified as having a disease or condition caused or exacerbated by intestinal hyperpermeabilization are additionally disclosed.Type: ApplicationFiled: April 27, 2012Publication date: July 31, 2014Applicant: Thomas Jefferson UniversityInventors: Scott A. Waldman, Adam E. Snook, Peng Li, Jieru Egeria Lin
-
Publication number: 20140213535Abstract: Flavonol compounds, pharmaceutical compositions of the compounds and methods for treating bone disorders by administering the pharmaceutical composition by oral, intravenous, subcutaneous, intra-peritoneal or intramuscular route.Type: ApplicationFiled: January 20, 2014Publication date: July 31, 2014Applicant: Council of Scientific & Industrial ResearchInventors: Rakesh MAURYA, Preeti RAWAT, Kunal SHARAN, Jawed Akhtar SIDDIQUI, Gaurav SWARNKAR, Geetanjali MISHRA, Lakshmi MANICKAVASAGAM, Girish Kumar JAIN, Kamal Ram ARYA, Naibedya CHATTOPADHYAY
-
Publication number: 20140213536Abstract: Zanthoxylum piperitum (commonly known as Japanese pepper) seeds, including its mature seeds, contain the NMS precursor N-methylserotonin S-O-6-glucoside (“NMS-glucoside”) present in sufficient concentration and are metabolized with sufficient efficiency so as to provide an effective amount of NMS for use in amelioration of menopausal symptoms, including hot flashes/flushes. The Japanese pepper seeds or Japanese pepper seed extracts can also be used to enrich other sources of NMS or NMS precursors in order to provide a nutraceutical or food supplement for controlling hot flashes. This invention relates to the marketing of nutraceuticals and food supplements containing these ingredients. Target customers include perimenopausal women, menopausal women and post menopausal women who wish to reduce the risk of experiencing hot flashes.Type: ApplicationFiled: January 24, 2014Publication date: July 31, 2014Applicant: DSM IP ASSETS B.V.Inventors: Christopher Michael BUTT, Michael WEISER
-
Publication number: 20140213537Abstract: The invention relates to extracts and compositions from Gnetum africanum. It also concerns plant extracts enriched in resveratrol and methods for obtaining the same. Described herein are processed plant materials which comprise about 20 ?g resveratrol per gram of dried plant material and plant extracts which comprise at least about 0.002% w/w resveratrol. Also described are resveratrol glycosides and compositions comprising same. The invention further encompasses food products, nutraceutical products, pharmaceutical compositions which comprise processed plant materials, plant extracts and/or resveratrol glycosides.Type: ApplicationFiled: July 26, 2011Publication date: July 31, 2014Applicant: PHARMAFRI-CAN INC.Inventors: Carole Robert, Sue Wehner
-
Publication number: 20140213538Abstract: Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one or more of the lysophosphatidic acid receptors are provided.Type: ApplicationFiled: January 15, 2014Publication date: July 31, 2014Inventors: Brad Owen Buckman, John Beamond Nicholas, Kumaraswamy Emayan, Scott D. Seiwert, Shendong Yuan
-
Publication number: 20140213539Abstract: Disclosed is a synthesis suitable for large scale manufacture of an A2A-adenosine receptor agonist, and also relates to polymorphs of that compound, and to methods of isolating a specific polymorph.Type: ApplicationFiled: August 19, 2013Publication date: July 31, 2014Applicant: Gilead Sciences, Inc.Inventors: Jeff Zablocki, Elfatih Elzein, Robert Seemayer, Travis Lemons
-
Publication number: 20140213540Abstract: 2? and/or 3? prodrugs of 1?, 2?, 3? or 4?-branched nucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are described. Methods and uses are also provided that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions.Type: ApplicationFiled: March 20, 2014Publication date: July 31, 2014Applicants: IDENIX PHARMACEUTICALS, INC., L'UNIVERSITE MONTPELLIER II, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITA DEGLI STUDI DI CAGLIARIInventors: Richard STORER, Gilles GOSSELIN, Jean-Pierre SOMMADOSSI, Paolo LACOLLA
-
Publication number: 20140213541Abstract: The present invention relates to a method for treating recurrent tumor metastases following liver resection that includes administration of an effective amount of an agonist of A2A adenosine receptors (ARs).Type: ApplicationFiled: October 7, 2013Publication date: July 31, 2014Applicant: ADENOSINE THERAPEUTICS, LLCInventors: Onno Kranenburg, Jamila van der Bilt, Inne Borel Rinkes, Jayson M Rieger
-
Publication number: 20140213542Abstract: The present invention relates to a composition including S-adenosyl-L-methionine; and at least one kind of additive selected from carboxymethylcellulose, hydroxypropylcellulose, soybean polysaccharide, casein sodium, and zein, in which S-adenosyl-L-methionine is extracted from S-adenosyl-L-methionine-containing cells obtained by culturing a microorganism having an ability to produce SAMe, and the content of the additive in the composition falls within the range of 0.05 to 15 times by mass of S-adenosyl-L-methionine in the composition. The present invention provides a composition containing a high concentration of S-adenosyl-L-methionine, which is useful as a water-soluble physiologically active substance, and being excellent in storage stability and bioabsorbability. The present invention also relates to a molded article formed by using the composition and a method of producing the composition.Type: ApplicationFiled: July 20, 2012Publication date: July 31, 2014Applicant: MITSUBISHI GAS CHEMICAL COMPANY, INC.Inventors: Kentaro Takano, Shinyo Gayama
-
Publication number: 20140213543Abstract: The invention provides a compound of formula (1), wherein R1-R6 and X have any of the values described, as well as pharmaceutical compositions comprising such compounds and therapeutic methods comprising the administration of such compounds.Type: ApplicationFiled: March 28, 2014Publication date: July 31, 2014Applicant: Regents of the University of MinnesotaInventor: Carston R. Wagner
-
Publication number: 20140213544Abstract: Plant treatment compositions comprising metal alginate salts and at least one amine compound are useful in the treatment of plants, particularly food crops. The metal alginate salts are found to be highly effective in the absence of herbicides, fungicides and pesticides.Type: ApplicationFiled: March 28, 2014Publication date: July 31, 2014Applicant: Cowan Co.Inventors: Wallace Keith Majure, Nicholas William Vandervort, Paul Joseph David, Brian Duane Deeter, Gary Joseph Melchior, James Richard Brazzle, Kenneth Roger Muzyk, Frank Rene Miranda, Tak Wai Cheung, Oaxford George Bain, John Edward Frieden, David Alexander Marsden, Olaf Christian Moberg, Susan Toddie Oeltjen, John Christopher Rueb, William Arthur Hendrickson
-
Publication number: 20140213545Abstract: The present invention relates to the field of nutraceuticals, and in particular to nutraceuticals comprising sulfated polysaccharides, Astragalus polysaccharides, resveratrol, and combinations thereof. These compositions find use in inducing physiological responses such, decreasing body fat, increasing lean body mass, alleviating the symptoms of colds, preventing the onset of colds, increasing energy, increasing the feeling of well-being in subjects, and improving skin tone and appearance.Type: ApplicationFiled: April 1, 2014Publication date: July 31, 2014Applicant: Life Science Nutrition ASInventor: Jan Remmereit
-
Publication number: 20140213546Abstract: Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and pharmaceutically acceptable salts thereof. In one aspect, hyaluronic acid-based compositions described herein include a therapeutically effective amount of at least one anesthetic agent, for example, lidocaine. The present hyaluronic acid-based compositions including lidocaine have an enhanced stability and cohesivity, relative to conventional compositions including lidocaine, for example when subjected to sterilization techniques or when stored for long periods of time. Methods and processes of preparing such hyaluronic acid-based compositions are also provided.Type: ApplicationFiled: April 1, 2014Publication date: July 31, 2014Applicant: Allergan Industrie SASInventor: Pierre F. Lebreton
-
Publication number: 20140213547Abstract: Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and pharmaceutically acceptable salts thereof. In one aspect, hyaluronic acid-based compositions described herein include a therapeutically effective amount of at least one anesthetic agent, for example, lidocaine. The present hyaluronic acid-based compositions including lidocaine have an enhanced stability and cohesivity, relative to conventional compositions including lidocaine, for example when subjected to sterilization techniques or when stored for long periods of time. Methods and processes of preparing such hyaluronic acid-based compositions are also provided.Type: ApplicationFiled: April 1, 2014Publication date: July 31, 2014Applicant: Allergan Industrie SASInventor: Pierre F. Lebreton
-
Publication number: 20140213548Abstract: The present invention relates a novel hemostatic wound dressing, preferably comprising chitosan and an oxygen carrier such as a perfluorocarbon, and methods to treat hemorrhaging wounds and MRSA infections. The present invention helps with coagulation/clot formation as well as providing oxygen to the wound, all while being cost effective and competitive with current hemostatic dressings.Type: ApplicationFiled: January 27, 2014Publication date: July 31, 2014Applicant: New Jersey Institute of TechnologyInventors: George J. Ulsh, Jennifer W. Moy, Maxwell A. McDermott, Dung T. Le, George Colling, Jessica Cardenas Turner
-
Publication number: 20140213549Abstract: The present invention provides a substituted pyridine compound or a pharmacologically acceptable salt thereof which has excellent CETP inhibition activity and is useful as a medicament. The present invention provides a compound represented by a general formula (I), wherein R1 is H, optionally substituted alkyl, OH, optionally substituted alkoxy, alkylsulfonyl, optionally substituted amino, carboxy, optionally substituted carbonyl, CN, halogeno, optionally substituted phenyl, optionally substituted aromatic heterocyclyl, optionally substituted saturated heterocyclyl, optionally substituted saturated heterocyclyloxy or optionally substituted saturated heterocyclylcarbonyl, etc., and the like.Type: ApplicationFiled: July 8, 2011Publication date: July 31, 2014Applicants: UBE INDUSTRIES, LTD., DAIICHI SANKYO COMPANY, LIMITEDInventors: Tsuyoshi Nakamura, Hidenori Namiki, Naoki Terasaka, Akiko Shima, Masahiko Hagihara, Noriaki Iwase, Katsunori Takata, Osamu Kikuchi, Kazunari Tsuboike, Hiroyuki Setoguchi, Kenji Yoneda, Hidetoshi Sunamoto, Koji Ito
-
Publication number: 20140213550Abstract: The invention provides silicate prodrugs comprising a therapeutic agent linked to one or more groups of formula (I): —Si(OR)3 (I); wherein each R independently has any of the values defined herein, as well as nanoparticles comprising such compounds.Type: ApplicationFiled: May 31, 2012Publication date: July 31, 2014Applicant: REGENTS OF THE UNIVERSITY OF MINNESOTAInventors: Thomas R. Hoye, Adam Wohl, Christopher W. Macosko, Jaynath Panyam
-
Publication number: 20140213551Abstract: This invention is related to compounds and/or compositions useful against pathogens affecting meats, plants, or plant parts. In one embodiment, the provided compounds are products of certain oxaborole moieties. In a further embodiment, the compound comprises a di-oxaborole compound. Delivery systems are also provided to take advantage of the volatile nature of these compounds and/or compositions.Type: ApplicationFiled: February 18, 2014Publication date: July 31, 2014Applicant: Dow AgroScience LLCInventors: Richard Martin Jacobson, Daniel Maclean, Esther Gachango
-
Publication number: 20140213552Abstract: The present application provides novel compounds and methods for preparing and using these compounds. These compounds are useful in treating pain, itch, overactive bladder and/or interstitial cystitis in patients by administering one or more of the compounds to a patient. The methods include administering a compound of formula (I) and a TRPV1 receptor activator. In one embodiment, the TRPV1 receptor activator is lidocaine.Type: ApplicationFiled: March 20, 2014Publication date: July 31, 2014Applicant: Endo Pharmaceuticals Inc.Inventors: Scott Kevin Thompson, Roger Astbury Smith, Sandeep Gupta, Tony Priestley, Nicholas James Laping, Ashis K. Saha, Sonali Rudra
-
Publication number: 20140213553Abstract: This invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an HIV integrase inhibitor.Type: ApplicationFiled: May 3, 2012Publication date: July 31, 2014Applicant: CONCERT PHARMACEUTICALS INC.Inventor: Adam Morgan
-
Publication number: 20140213554Abstract: Compounds active on c-kit protein kinases or mutant c-kit protein kinases having any mutations are described, as well as methods of making and using such compounds to treat diseases and conditions associated with aberrant activity of the c-kit protein kinases and/or mutant c-kit protein kinases.Type: ApplicationFiled: December 20, 2013Publication date: July 31, 2014Inventors: Guoxian Wu, Katrina Chan, Todd Ewing, Prabha N. Ibrahim, Jack Lin, Marika Nespi, Wayne Spevak, Ying Zhang
-
Publication number: 20140213555Abstract: Compounds and embodiments of a method for treating and/or preventing autoimmune diseases are disclosed. The method includes administering to a subject having an autoimmune disease, such as an inflammatory bowel disease, a therapeutically effective amount of a compound according to formula I wherein X and Y independently are O or NR1; each R1 is independently H or C1-C6 alkyl; ring A is aryl; each R2 independently is H, alkyl, alkoxy, amide, cyano, halo, haloalkyl, hydroxyalkyl, heteroalkyl, heterocyclyl, sulfonyl, sulfonamide, or two R2 groups, taken together with the atom or atoms to which they are attached, combine to form a 4-10 membered ring system; p is 0, 1, 2, 3, or 4; R3 and R4 independently are H or C1-C6 alkyl; and R5 is halo, cyano, or C1-C6 alkyl.Type: ApplicationFiled: January 24, 2014Publication date: July 31, 2014Applicant: Rigel Pharmaceuticals, Inc.Inventors: Esteban Masuda, Rajinder Singh, Vanessa Taylor, Donald G. Payan
-
Publication number: 20140213556Abstract: The present invention relates to therapeutic combinations of [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester (tenofovir disoproxil fumarate, Viread®) and (2R,5S,cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine, Emtriva™, (?)-cis FTC) and their physiologically functional derivatives. The combinations may be useful in the treatment of HIV infections, including infections with HIV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors. The present invention is also concerned with pharmaceutical compositions and formulations of said combinations of tenofovir disoproxil fumarate and emtricitabine, and their physiologically functional derivatives, as well as therapeutic methods of use of those compositions and formulations.Type: ApplicationFiled: March 27, 2014Publication date: July 31, 2014Applicant: GILEAD SCIENCES, INC.Inventors: Terrence C. DAHL, Mark M. MENNING, Reza OLlYAI
-
Publication number: 20140213557Abstract: The present invention relates to novel active compound combinations comprising, firstly, a known herbicide selected from the group consisting of glyphosate, glufosinate and glufosinate-ammonium and, secondly, at least one known fungicidally active compound, which combination is highly suitable for controlling unwanted phytopathogenic fungi, in particular soya bean rust. Particular preference is given to using these mixtures on transgenic plants resistant to the herbicides mentioned.Type: ApplicationFiled: March 28, 2014Publication date: July 31, 2014Applicant: Bayer CropScience AGInventors: Klaus STENZEL, Markus Dollinger, Peter Dahmen, Ulrike Wachendorff-Neumann, Isolde Häuser-Hahn, Marie-Claire Grosjean, Bernard Marc Leroux, Haruko Sawada, Hiroyuki Hadano, Jean-Marie Gouot, Christian Scherb
-
Publication number: 20140213558Abstract: Embodiments of the invention relate generally to the treatment of inflammatory diseases and disorders and, more particularly, to the treatment of symptoms of inflammatory diseases and disorders using thymoquinone (TQ) alone or in combination with other compounds, including eicosapentaenoic acid (EPA). In one embodiment, the invention provides a pharmaceutical composition suitable for the treatment of at least one symptom of an inflammatory disease or disorder, comprising: an effective amount of thymoquinone; and at least one physiologically-acceptable carrier, wherein an effective amount of thymoquinone is an amount capable of reducing or preventing the at least one symptom of the inflammatory disease or disorder.Type: ApplicationFiled: August 17, 2012Publication date: July 31, 2014Applicant: CREDE OILS (PTY) LTDInventor: Philipp Crede
-
Publication number: 20140213559Abstract: The present invention provides an inhibitor of intracellular protein degradation for use in the treatment and prevention of muscular dystrophy in a mammal. In particular, the invention provides an autophagy inhibitor and/or an inhibitor of the ubiquitin-proteasome system (such as a proteasome inhibitor) for use in the treatment and prevention of muscular dystrophy (such as congenital muscular dystrophy [e.g. MDC1A) and Duchenne muscular dystrophy [DMD]). The invention further provides corresponding methods of treatment and prevention of muscular dystrophy.Type: ApplicationFiled: May 27, 2011Publication date: July 31, 2014Applicant: MD PHARMA ABInventors: Madeleine Durbeej-Hjalt, Virginie Carmingnac
-
Publication number: 20140213560Abstract: The present disclosure relates to pharmaceutical compositions useful for (and to a method of) treating autoimmune, respiratory and/or inflammatory diseases and conditions. The method involves administering to a subject in need thereof roflumilast N-oxide by inhalation. The present disclosure particularly relates to the treatment of asthma and chronic obstructive pulmonary disease (COPD) by administering roflumilast N-oxide by inhalation.Type: ApplicationFiled: January 28, 2014Publication date: July 31, 2014Applicant: Incozen Therapeutics Pvt. Ltd.Inventor: Swaroop K. VAKKALANKA
-
Publication number: 20140213561Abstract: A gatifloxacin and prednisolone topical ophthalmic pharmaceutical compositions for prevention and treatment of ophthalmic bacterial infections and inflammatory conditions associated with pre-surgical and/or post surgical ocular surgeries.Type: ApplicationFiled: March 28, 2014Publication date: July 31, 2014Applicant: Allergan, Inc.Inventor: Kothanda Raman T. RAJAN
-
Publication number: 20140213562Abstract: Methods relating to local injections of corticosteroids are provided. More specifically intralesional injections of corticosteroids and preferably Triamcinolone and its derivatives are suitable to produce medicaments to be injected in the subcutaneous fat at deep levels to provoke cosmetic lipoatrophy of small fat deposits on the face and body.Type: ApplicationFiled: April 2, 2014Publication date: July 31, 2014Inventor: Doris Hexsel
-
Publication number: 20140213563Abstract: This invention provides methods of diagnosing and treating syndromes of reversion to fetal consciousness in a neonate.Type: ApplicationFiled: January 24, 2014Publication date: July 31, 2014Applicant: The Regents of the University of CaliforniaInventors: John E. MADIGAN, Monica R. ALEMAN
-
Publication number: 20140213564Abstract: The present invention relates to improved topical gel compositions comprising an active agent, and uses thereof.Type: ApplicationFiled: July 12, 2013Publication date: July 31, 2014Inventors: Bhushan HARDAS, Donna Dalton, Petra Scheppler, Anja Hensche, Peter Boderke
-
Publication number: 20140213565Abstract: According to various embodiments of this disclosure, pharmaceutical formulations comprising solubilized estradiol are provided. In various embodiments, such formulations are encapsulated in soft capsules which may be vaginally inserted for the treatment of vulvovaginal atrophy.Type: ApplicationFiled: December 20, 2013Publication date: July 31, 2014Applicant: TherapeuticsMD, Inc.Inventors: Brian A. Bernick, Julia M. Amadio, Peter H.R. Persicaner, Thorsteinn Thorsteinsson, Janice Louise Cacace
-
Publication number: 20140213566Abstract: Pharmaceutical compositions and methods for treating or preventing bacterial infections are disclosed. The pharmaceutical compositions typically comprise pharmaceutically effective amount of: (a) at least one beta-lactam antibiotic or a pharmaceutically acceptable salt thereof, (b) sulbactam or a pharmaceutically acceptable salt thereof, and (c) at least one beta-lactamase inhibitor or a pharmaceutically acceptable salt thereof, with the provision that the beta-lactamase inhibitor is not sulbactam.Type: ApplicationFiled: October 4, 2011Publication date: July 31, 2014Applicant: Wockhardt LimitedInventors: Sachin Subhash Bhagwat, Mahesh Vithalbhai Patel
-
Publication number: 20140213567Abstract: This disclosure provides compositions comprising a beta-lactam compound and crystalline tazobactam arginine, and related methods and uses of these compositions.Type: ApplicationFiled: March 28, 2014Publication date: July 31, 2014Inventors: Jan-Ji Lai, Jian-Qiao Gu, Pradip M. Pathare, Valdas Jurkauskas, Joseph Terracciano, Nicole Miller Damour
-
Publication number: 20140213568Abstract: The invention relates to new pyrrolidine derivatives of the formula to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.Type: ApplicationFiled: January 22, 2014Publication date: July 31, 2014Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Martin FLECK, Niklas HEINE, Bernd NOSSE, Gerald Juergen ROTH
-
Publication number: 20140213569Abstract: Substituted 6-amino-nicotinamides, pharmaceutical compositions containing these compounds and also use of these compounds in the treatment and/or prophylaxis of pain and further diseases and/or disorders.Type: ApplicationFiled: March 31, 2014Publication date: July 31, 2014Applicant: GRUNENTHAL GMBHInventors: Sven KÜHNERT, Gregor BAHRENBERG, Achim KLESS, Wolfgang SCHRÖDER, Simon LUCAS
-
Publication number: 20140213570Abstract: The present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.Type: ApplicationFiled: April 1, 2014Publication date: July 31, 2014Applicant: NOVARTIS AGInventors: Atwood Kim CHEUNG, Donovan Noel CHIN, Natalie DALES, Aleem FAZAL, Timothy HURLEY, John KERRIGAN, Gary O'BRIEN, Lei SHU, Robert SUN, Moo Je SUNG
-
Publication number: 20140213571Abstract: The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.Type: ApplicationFiled: August 20, 2012Publication date: July 31, 2014Inventors: Nigel J. Liverton, Casey Cameron McComas, Joerg Habermann, Uwe Koch, Frank Narjes, Peng Li, Xuanjia Peng, Richard Soll, Hao Wu, Anandan Palani, Shuwen He, Xing Dai, Hong Liu, Zhong Lai, Clare London, Dong Xiao, Nicolas Zorn, Ravi Nargund
-
Publication number: 20140213572Abstract: Unsaturated nitrogen heterocyclic compounds of formula (I): as defined in the specification, compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, Huntington's Disease, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.Type: ApplicationFiled: April 1, 2014Publication date: July 31, 2014Applicant: AMGEN INC.Inventors: Jennifer R. Allen, Jian J. Chen, Michael J. Frohn, Essa Hu Harrington, Qingyian Liu, Alexander J. Pickrell, Shannon Rumfelt, Robert M. Rzasa, Wenge Zhong
-
Publication number: 20140213573Abstract: The present invention relates to novel benzyl azetidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.Type: ApplicationFiled: April 2, 2014Publication date: July 31, 2014Applicant: Allergan, Inc.Inventors: Wenkui K. Fang, Liming Wang, Ken Chow, Evelyn G. Corpuz, Wha Bin Im
-
Publication number: 20140213574Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.Type: ApplicationFiled: April 16, 2014Publication date: July 31, 2014Applicant: Celgene Avilomics Research, Inc.Inventors: Juswinder Singh, Russell Petter, Richland Wayne Tester, Arthur F. Kluge, Hormoz Mazdiyasni, William Frederick Westlin, III, Deqiang Niu, Lixin Qiao
-
Publication number: 20140213575Abstract: The invention relates to 6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepines, in particular for therapeutic purposes, pharmaceutical agents and use thereof in therapy, in particular for the prevention and treatment of tumour diseases.Type: ApplicationFiled: August 27, 2012Publication date: July 31, 2014Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Norbert Schmees, Joachim Kuhnke, Bernard Haendler, Philip Lienau, Amaury Ernesto Fernandez-Montalvan, Pascale Lejeune, Stephan Siegel, William Scott
